Search results for: 'Drug Discovery and Early Development Outsourcing Market'

Organizations across the board realize the significance of delivering excellent customer service as a competitive differentiator. Customer experience (CX) outsourcing services play an increasingly vital role in building a robust end-to-end customer journey as customer-centricity takes center stage. Providing contextual, proactive, seamless, and per...

22 Aug 2022  |  North America  |  Frost Radar

Frost Radar™ for Economic Development: The United States, 2022

Texas, California and Georgia Emerge as Top States for Demonstrating Strong Investment Potential

Infographics

×

Key Issues Addressed

The Frost Radar™ for Economic Development for the United States determines the investment potential for each state measured by favorable state policies that will effectively drive inward investment and that are driven by social factors. This report explores key strengths and weaknesses of the the US economy through state-level assessments of growt...

13 Oct 2023  |  Global  |  Market Research

Global Outsourced Semiconductor Assembly and Test Growth Opportunities

Increasing Adoption of Advanced Packaging and the Need for Cost-effective ATP Solutions will Fuel Transformational Growth

Infographics

×

This study analyzes the global outsourced semiconductor assembly and test (OSAT) market, which is set to experience substantial growth driven by the increasing adoption of advanced packaging technology across various industries. OSATs are third-party providers that specialize in assembly, testing, and packaging (ATP) services and cater to integrate...

During the forecast period (2023 to 2029), the North American (NA) customer experience (CX) outsourcing services market is expected to expand, mainly due to 2 factors: 1) the growing recognition of CX as a potent tool for competitive advantage and 2) the increasing motivation for businesses to outsource their CX activities. This market is poised...

As the industry continues to innovate across novel small- and large-molecule therapies, including RNA-targeted small molecules, cell and gene therapies, and mRNA therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.These disruptions continue to drive ...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmol...

25 Sep 2025  |  Global  |  Technology Research

Growth Opportunities in Computational Quantum Chemistry for Accelerated Material Discovery

Harnessing Quantum Algorithms and Simulation Platforms to Transform Material R&D Across Industries

Infographics

×

As global industries confront increasing demands for sustainability, performance, and innovation in materials R&D, computational quantum chemistry is emerging as a crucial enabler in the coming years. By simulating matter at the electron level, quantum chemistry allows for highly accurate predictions of molecular behavior, driving breakthroughs in ...

Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate. Digital bio...